Richard L. Piekarz
Departmentof Health and Human Services
Center for Cancer Researchand Cancer Therapy EvaluationProgram
National Cancer Institute
National Institutes of Health
USA
Name/email consistency: high
- Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. Piekarz, R.L., Frye, R., Turner, M., Wright, J.J., Allen, S.L., Kirschbaum, M.H., Zain, J., Prince, H.M., Leonard, J.P., Geskin, L.J., Reeder, C., Joske, D., Figg, W.D., Gardner, E.R., Steinberg, S.M., Jaffe, E.S., Stetler-Stevenson, M., Lade, S., Fojo, A.T., Bates, S.E. J. Clin. Oncol. (2009)
- Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Piekarz, R.L., Sackett, D.L., Bates, S.E. Cancer. J (2007)
- Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Piekarz, R.L., Frye, A.R., Wright, J.J., Steinberg, S.M., Liewehr, D.J., Rosing, D.R., Sachdev, V., Fojo, T., Bates, S.E. Clin. Cancer Res. (2006)
- T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Piekarz, R.L., Robey, R.W., Zhan, Z., Kayastha, G., Sayah, A., Abdeldaim, A.H., Torrico, S., Bates, S.E. Blood (2004)
- Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Piekarz, R.L., Robey, R., Sandor, V., Bakke, S., Wilson, W.H., Dahmoush, L., Kingma, D.M., Turner, M.L., Altemus, R., Bates, S.E. Blood (2001)